A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT

Recruiting

Interventions: Device: Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System

Brief Summary: This investigation is a prospective, multi-center clinical investigation. It is anticipated that a total of 50 subjects will be enrolled. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System.

Total duration of enrollment, 12 month follow-up and analysis is expected to take 25 months. The clinical investigation has been designed to follow the surgeon's standard of care for femur fractured subjects, in addition to a 12 month follow-up visit.

The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the Lower Extremity Measure (LEM). Confirmation of efficacy/performance at 12 months will be based on an equal or greater (non-inferior) LEM score result of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature.

Detailed Description: The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System. Efficacy/performance of the procedure will be measured by an equal or greater (non-inferior) Lower Extremity Measure (LEM) score result of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature at 12 months.

In addition, demonstration of bone consolidation in correct alignment will be measured by Investigator assessment by 12 months. Safety of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System will be demonstrated through reporting of device related intra-operative and post-operative Adverse Events/incidents by 12 months.

Recruitment & Eligibility

Inclusion Criteria

Subject is a male or non-pregnant female age 18 years or older at the time of surgery;
Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;
Subject is intended to be treated with the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System in accordance with the following legally cleared/ approved Indications for Use:

Indications for Use approved Outside of Europe include:

Fixation of subtrochanteric, intertrochanteric, ipsilateral neck/shaft, comminuted proximal femoral shaft fractures
Femoral fixation required as a result of pathological disease
Temporary stabilization of fractures of the femoral shaft ranging from the femoral neck to the supracondylar regions of the femur
Open and closed femoral fractures
Pseudoarthrosis and correction osteotomy
Pathologic fractures, impending pathologic fractures and tumor resections
Ipsilateral femur fractures
Fractures proximal to a total knee arthroplasty
Nonunions and malunions
Fractures involving osteopenic and osteoporotic bone

Exclusion Criteria

Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).

Arm && Interventions

Group	Intervention	Description
T2 Alpha Femoral Nail GT	Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System	Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.

Primary Outcome Measures

Name	Time	Method
Lower Extremity Measure (LEM)	12 months	The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the Lower Extremity Measure (LEM). Confirmation of efficacy/performance at 12 months will be based on an equal or greater (non-inferior) LEM score result of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature

Secondary Outcome Measures

Name	Time	Method
Efficacy/Performance will be measured by demonstration of bone consolidation	12 months	Bone consolidation will be assessed by 12 months as measured by Investigator assessment.
Safety will be measured by capturing the incidence rate of device-related adverse events	12 months	Incidence of device-related adverse events will be monitored by 12 months through data collection and analyses.

Locations (6): Regional One Health
🇺🇸
Memphis, Tennessee, United States
St. Cloud Orthopedic Associates, Ltd
🇺🇸
Sartell, Minnesota, United States
Reno Orthopedic Clinic
🇺🇸
Reno, Nevada, United States
New York University
🇺🇸
New York, New York, United States
UC Health
🇺🇸
Cincinnati, Ohio, United States
Inova Fairfax Medical Campus
🇺🇸
Falls Church, Virginia, United States